Boehringer Ingelheim has entered into a multi-year strategic partnership with TARGET PharmaSolutions, a real-world clinical data company, for an observational study TARGET-NASH.
This study is evaluating patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and has enrolled 2,423 patients at 55 sites, with the expectation to enroll as many as 15,000 patients over the coming years.
The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, investigators, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.
Meg Powell, chief executive officer of TARGET PharmaSolutions, said, "We are very excited to have Boehringer Ingelheim join TARGET-NASH as an industry partner. We have exceeded our enrollment targets to date, and we are providing valuable real-world data and insight on NASH patients that will have a significant impact on the scientific understanding of the natural history and treatment modalities for NASH. This data, combined with the TARGET-NASH biorepository and patient reported outcomes, will enable our collaborators to continue to increase their understanding of this growing disease."
Breaking News
Boehringer, TARGET Pharma in Strategic NASH Pact
Observational study to incorporate TARGET model of community of stakeholders
10.19.17
Related Breaking News
-
Breaking News | Industry News | Information Technology | Packaging & Tracking | Serialization
GS1 US Launches EPCIS Conformance Testing Program
Drummond Group certified as first conformance testing service11.13.18
-
Analytical Services | Bio News | Industry News | Information Technology
Zenith Technologies Launches Mfg. Training System
New virtual customized training service to tackle critical gaps in industry manufacturing software and process training11.13.18
-
Breaking News | Clinical Trials | Collaborations & Alliances | CRO News | Information Technology
SHYFT Analytics, PAREXEL Enter Strategic RWE Pact
Will leverage SHYFT’s technology for Real-World Evidence generation and outcomes research11.12.18
-
Breaking News | Clinical Trial Materials | Clinical Trials | Drug Development | Industry News
Ziopharm, Regeneron In Clinical Supply Pact
Will evaluate Ziopharm’s Ad-RTS-hIL-12 plus veledimex with Regeneron’s PD-1 antibody Libtayo in recurrent glioblastoma11.12.18
-
Bio News | Clinical Trials | Industry News | R&D | Trials & Filings
Janssen Receives FDA Approval for INVOKANA
To reduce risk of major adverse cardiovascular events, in adults with type 2 diabetes (T2D) who have established CV disease10.30.18
-
Breaking News | Clinical Trials | CRO News
Rho Joins Avoca Quality Consortium
Gains access to AQC Knowledge Center with leading practices, guidelines, tools, and templates aimed at improving quality10.30.18
-
Analytical Services | Breaking News | Collaborations & Alliances | Drug Discovery | Information Technology
Charles River, Distributed Bio in Exclusive Antibody Discovery Pact
Gains access to Distributed Bio’s antibody libraries and integrated antibody optimization technologies10.25.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
Kazia, Dana-Farber Cancer Institute Partner for Cancer
To investigate use of Kazia’s potential new therapy for brain cancer, GDC-0084, in breast cancer that has spread to the brain10.22.18
-
Bio News | Clinical Trials | Collaborations & Alliances | Industry News | R&D
LSKB, Hengrui Enter Clinical Collaboration
To evaluate the safety & efficacy of LSKB's rivoceranib, known as apatinib or Aitan® in China with Hengrui's camrelizumab10.22.18
-
Analytical Services | Bio News | Collaborations & Alliances | Industry News | Information Technology
Roche Selects IQVIA’s Technology Suite
Roche will rollout IQVIA’s OCE Sales, OCE Marketing, Organization Manager, MDM, and ePromo solutions for around 14,000 users10.18.18
-
Bio News | Clinical Trials | Industry News | Promotions & Moves
Quanticate Appoints Data Management VP
Deepu Joseph will also serve as the company's global head and the site head of Bangalore10.18.18
-
Bio News | Clinical Trials | Drug Development | Industry News | R&D | Trials & Filings
JHL Biotech Receives NMPA Approval
For Phase I & Phase III clinical trial applications for a proposed bevacizumab biosimilar, JHL1149, to treat forms of cancer10.15.18
-
Bio News | Clinical Trials | Drug Discovery | Industry News | R&D
Almac Adds Illumina NovaSeq 6000
The sequencer aims to benefit Biopharma clients’ biomarker discovery and clinical trial projects10.12.18
-
Analytical Services | Bio News | Bioanalytical Services | Collaborations & Alliances | Industry News | Information Technology | R&D
Allergan Joins TriNetX Network
For real-time access to patient populations to determine protocol feasibility, cohort analysis and site identification10.10.18
-
Analytical Services | Bio News | Breaking News | Industry News | Information Technology | Methods Development
MilliporeSigma Launches Chemiflex Program
To help process development scientists solve raw material quality, regulatory & procurement challenges for small molecule mfg10.08.18
